SCHEDULE: T. Rowe Price Discloses 7.1% Stake in Avidity Biosciences
Beneficial Ownership Report (Schedule 13G)
T. Rowe Price Associates, Inc. has reported a 7.1% beneficial ownership stake in Avidity Biosciences Inc. common stock as of September 30, 2025.
Summary
- T. Rowe Price Associates, Inc. holds an aggregate of 9,787,912 shares of Avidity Biosciences Inc. common stock.
- This beneficial ownership represents 7.1% of the total class of securities.
- T. Rowe Price Associates, Inc. possesses sole voting power over 9,583,549 shares.
- T. Rowe Price Associates, Inc. holds sole dispositive power over 9,787,417 shares.
- The filing is an Amendment No. 7 to a Schedule 13G, indicating an update to a previously reported position.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership by an institutional investor, not a performance or strategic announcement.
Future Outlook
NA
Management Comments
- T. Rowe Price Associates, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of Avidity Biosciences Inc.
- T. Rowe Price Associates, Inc. expressly denies beneficial ownership of the securities referred to in the filing, consistent with its role as an investment adviser managing assets on behalf of clients.
Industry Context
This filing indicates continued institutional interest in Avidity Biosciences, with T. Rowe Price, a major investment adviser, maintaining a significant stake. Such disclosures provide transparency into large institutional holdings, which can influence market perception and liquidity for the issuer within the biotechnology sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially influencing market sentiment and liquidity.
- Company Management: Awareness of a large institutional investor's position, which may imply a degree of oversight or potential engagement.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement |
| 11/14/2025 | Signature date of the filing |
Keywords
Avidity Biosciences, T. Rowe Price, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.